



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Myriam GOLEMBO et al.

Confirmation No.: 3940

Application No.: 10/664,605

Group Art Unit: 1646

Filing Date: September 15, 2003

Examiner:

For: METHOD AND COMPOSITION FOR
TREATMENT OF SKELETAL DYSPLASIAS

Attorney Docket No.: 81408-4300

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to Applicants' duty of disclosure under 37 C.F.R. § 1.56, enclosed is a Form PTO-1449 containing a total of 38 references for the Examiner's review and consideration. Copies of non-U.S. patent references labeled B1 and C1-C24 are enclosed herewith. Copies of U.S. patent references A1-A13 will be provided if the Examiner so requests.

It is respectfully requested that the references be made of record in this application by the Examiner's completion and return of the enclosed Form PTO-1449. While no representation is made that any of these references may be "prior art" within the meaning of that term under 35 U.S.C. Sections 102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of disclosure set forth in 37 C.F.R. Section 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that the references listed, together with any other references which may have been previously cited by or submitted to the Office, are the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b), before the latter of three months after the U.S. patent application filing date or prior to the mailing date of a first Office Action on the merits. Accordingly, no fee or certification is required. Should


any fees be required, however, please charge such fees to Winston & Strawn LLP Deposit
Account No. 50-1814.

Respectfully submitted,

3/19/04
Date

Rodney J. Fuller
Rodney J. Fuller (Reg. No. 46,714)
For: Allan A. Fanucci (Reg. No. 30,256)

WINSTON & STRAWN LLP
Customer No. 28765
202-371-5904


LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 (Use several sheets if necessary)		ATTY. DOCKET NO.:	APPLICATION NO.:
		81408-4300	10/664,605
		APPLICANT:	
		Myriam GOLEMBO et al.	
Sheet 1 of 2		FILING DATE:	GROUP:
		September 15, 2003	1646

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	CITE NO.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,683,195	07/1987	Mullis et al.	435	6	
	A2	4,683,202	07/1987	Mullis	435	91.2	
	A3	4,965,188	10/1990	Mullis et al.	435	6	
	A4	5,336,759	08/1994	Matsuo et al.	530	326	
	A5	5,338,759	08/1994	Shechter et al.	514	492	
	A6	5,434,133	07/1995	Tanaka et al.	514	12	
	A7	5,846,932	12/1998	Lowe et al.	514	9	
	A8	5,973,134	10/1999	Matsuo et al.	536	23.53	
	A9	6,020,168	02/2000	Matsuo et al.	435	69.4	
	A10	6,034,231	03/2000	Tanaka et al.	536	23.51	
	A11	2001/0025026	09/2001	Heartlein et al.	514	12	
	A12	6,329,375	12/2001	Tang et al.	514	250	
	A13	6,344,459	02/2002	Bridges et al.	514	234.5	

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1	WO 00/61631	10/2000	WIPO	C07K	14/58		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C1	Agrawal, S. et al., "Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 88, pp. 7595-7599 (1991).
	C2	Brandt, R.R. et al., "Neutral Endopeptidase Regulates C-Type Natriuretic Peptide Metabolism But Does Not Potentiate Its Bioactivity In Vivo," <i>Hypertension</i> , Vol. 30, No. 2, pp. 184-190 (1997).
	C3	Chang, P.L., "Microcapsules as Bio-organs for Somatic Gene Therapy," <i>Annals New York Academy of Sciences</i> , Vol. 831, pp. 460-473 (1997)
	C4	Chen, H.H. et al., "C-Type Natriuretic Peptide: The Endothelial Component of the Natriuretic Peptide System," <i>J. of Cardiovasc. Pharmacol.</i> , Vol. 32, Suppl. 3, pp. S22-S28 (1998).
	C5	Chen, H.H. et al., "Natriuretic Peptides in the Pathophysiology of Congestive Heart Failure," <i>Curr. Cardiol. Rev.</i> , Vol. 2, pp. 198-205 (2000).
	C6	Chusho, H. et al., "Dwarfism and early death in mice lacking C-type natriuretic peptide," <i>PNAS</i> , Vol. 98, No. 7, pp. 4016-4021 (2001).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 (Use several sheets if necessary)		ATTY. DOCKET NO.:	APPLICATION NO.:
		81408-4300	10/664,605
 Sheet 2 of 2		APPLICANT:	
		Myriam GOLEMBO et al.	
		FILING DATE:	GROUP:
		September 15, 2003	1646

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C7	Fingl, E. et al., "Chapter 1--General Principles," in The Pharmacological Basis of Therapeutics 5th edition, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975).	
C8	Harvey, C.B. et al., "Molecular Mechanisms of Thyroid Hormone Effects on Bone Growth and Function," <i>Molecular Genetics and Metabolism</i> , Vol. 75, pp. 17-30 (2002).	
C9	Kelly, P.A. et al., "Growth Hormone Receptor Signalling and Actions in Bone Growth," <i>Hormone Research</i> , Vol. 55 (suppl. 2), pp. 14-17 (2001).	
C10	Kridel, S.J. et al., "Substrate Hydrolysis by Matrix Metalloproteinase-9," <i>J. Biol. Chem.</i> , Vol. 276, No. 23, pp. 20572-20578 (2001).	
C11	Matsukawa, N. et al., "The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 96, pp. 7403-7308 (1999).	
C12	McCarthy, T.L. et al., "Local IGF-I expression and bone formation," <i>Growth Hormone & IGF Research</i> , Vol. 11, pp. 213-219 (2001).	
C13	Meriq, V. et al., "Regulation of Fetal Rat Bone Growth by C-Type Natriuretic Peptide and cGMP," <i>Pediatric Research</i> , Vol. 47, No. 2, pp. 189-193 (2000).	
C14	Murthy, K.S. et al., "Identification of the G Protein-activating Domain of the Natriuretic Peptide Clearance Receptor (NPR-C)," <i>J. Biol. Chem.</i> , Vol. 274, No. 25, pp. 17587-17592 (1999).	
C15	Ohbayashi, H. et al., "Neutral endopeptidase 3.4.24.11 Inhibition Potentiates the Inhibitory Effects of Type-C Natriuretic Peptide on Leukotriene D ₄ -Induced Airway Changes," <i>Clin. Exp. Pharma. Physiol.</i> , Vol. 25, pp. 986-991 (1998).	
C16	Pillai, O. et al., "Polymers in drug delivery," <i>Curr. Opin. Chem. Biol.</i> , Vol. 5, pp. 447-451 (2001).	
C17	Rousseau, F. et al., "Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia," <i>Nature</i> , Vol. 371, pp. 252-254 (1994).	
C18	Schweitz, H. et al., "A New Member of the Natriuretic Peptide Family Is Present in the Venom of the Green Mamba (<i>Dendroaspis angusticeps</i>)," <i>J. Biol. Chem.</i> , Vol. 267, No. 20, pp. 13928-13932 (1992).	
C19	Shiang, R. et al., "Mutations in the Transmembrane Domain of FGFR3 Cause the Most Common Genetic Form of Dwarfism, Achondroplasia," <i>Cell</i> , Vol. 78, pp. 335-342 (1994).	
C20	Suda, M. et al., "Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp. 2337-2342 (1998).	
C21	Vajo, Z. et al., "The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans," <i>Endocrine Reviews</i> , Vol. 21, No. 1, pp. 23-39 (2000).	
C22	Van Leeuwen, J.P.T.M. et al., "24,25-Dihydroxyvitamin D ₃ and bone metabolism," <i>Steroids</i> , Vol. 66, pp. 375-380 (2001).	
C23	Yamashita, Y. et al., "Concentration of mRNA for the Natriuretic Peptide Receptor-C in Hypertrophic Chondrocytes of the Fetal Mouse Tibia," <i>J. Biochem.</i> , Vol. 127, pp. 177-179 (2000).	
C24	Yasoda, A. et al., "Natriuretic Peptide Regulation of Endochondral Ossification," <i>J. Biol. Chem.</i> , Vol. 273, No. 19, pp. 11695-11700 (1998).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	